Drug intervention for freezing of gait resistant to dopaminergic therapy: A pilot study

Parkinsonism and Related Disorders

Volumn 12, Issue SUPPL. 2, 2006, Pages

  Kondo, Tomoyoshi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Freezing; Gait; PSP; Pure akinesia; Therapy

Indexed keywords

AMANTADINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; SELEGILINE; THREO 3,4 DIHYDROXYPHENYLSERINE;

AKINESIA; ARTICLE; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FREEZING GAIT; GAIT DISORDER; HUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

EID: 33749060874     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2006.05.018     Document Type: Article

References (28)

1. Ambani L.M., and Van Woert M.H. Start hesitation-a side effect of long-term levodopa therapy. N Engl J Med 288 21 (1973) 1113-1115
2. Narabayashi H. Clinical analysis of akinesia. J Neural Transm Suppl 16 (1980) 129-136
3. Imai H., Nakamura T., Kondo T., and Narabayashi H. Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?. Adv Neurol 60 (1993) 622-625
4. Narabayashi H., and Kondo T. Results of double-blind study of L-threo-DOPS in parkinsonism. In: Fahn S., Marsden C.D., Goldstein M., and Calne D.B. (Eds). Recent development in Parkinson's disease (1987), Macmillan Healthcare Information, New Jersey 279-291
5. Litvan I., Agid Y., Jankovic J., Goetz C., Brandel J.P., Lai E.C., et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 46 4 (1996) 922-930
6. Imai H. Syndrome of pure akinesia or freezing phenomenon without rigidity and tremor and with no effect by L-DOPA therapy. Dav Neurol Sci 24 (1980) 838-848
7. Kato N., Arai K., and Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci 210 1-2 (2003) 57-60
8. Giladi N., Shabtai H., Simon E.S., Biran S., Tal J., and Korczyn A.D. Construction of freezing of gait questionnaire for patients with Parkinsonism. Parkinsonism Relat Disord 6 3 (2000) 165-170
9. Sugimoto H., Iimura Y., Yamanishi Y., and Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl) methyl] piperidine hydrochloride and related compounds. J Med Chem 38 (1995) 4821-4829
10. Brannan T., Bhardwaj A., and Yahr M.D. L-threodops increases extracellular norepinephrine levels in the brain: an in vivo study. Neurology 40 (1990) 1134-1135
11. Stoof J.C., Booij J., Drukarch B., and Wolters E.C. The anti-parkinsonian drug amantadine inhibits the N-methyl-d-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 213 (1992) 439-443
12. Glover V., Elsworth J.D., and Sandler M. Dopamine oxidation and its inhibition by (-)-deprenyl in man. J Neural Transm Suppl 16 (1980) 163-172
13. Knoll J., Yoneda F., Knoll B., Ohde H., and Miklya I. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Br J Pharmacol 128 (1999) 1723-1732
14. Giladi N., Treves T.A., Simon E.S., Shabtai H., Orlov Y., Kandinov B., et al. Freezing of gait in patients with advanced Parkinson's disease. J Neural Transm 108 1 (2001) 53-61
15. Yamanouchi H., and Nagura H. Neurological signs and frontal white matter lesions in vascular parkinsonism. A clinicopathologic study. Stroke 28 (1997) 965-969
16. Giladi N., McDermott M.P., Fahn S., Przedborski S., Jankovic J., Stern M., et al. Parkinson Study Group. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 56 12 (2001) 1712-1721
17. Jellinger K.A. Morphological substrates of mental dysfunction in Lewy body disease: an update. J Neural Transm Suppl 59 (2000) 185-212
18. Pahapill P.A., and Lozano A.M. The pedunculopontine nucleus and Parkinson's disease. Brain 123 Pt 9 (2000) 1767-1783
19. Saykin A.J., Wishart H.A., Rabin L.A., Flashman L.A., McHugh T.L., Mamourian A.C., et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 127 Pt 7 (2004) 1574-1583
20. Lee M.S., Rinne J.O., and Marsden C.D. The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med J 41 2 (2000) 167-184
21. Zweig R.M., Whitehouse P.J., Casanova M.F., Walker L.C., Jankel W.R., and Price D.L. Loss of pedunculopontine neurons in progressive supranuclear palsy. Ann Neurol 22 1 (1987) 18-25
22. Ueno E. Clinical and physiological study of apraxia of gait and frozen gait. Rinsho Shinkeigaku 29 (1989) 275-283
23. Yanagisawa N., Ueno E., Hayashi R., Tokuda T., and Takou K. Apraxia of gait and disorders in posture and locomotion. Rinsho Shinkeigaku 33 (1993) 1310-1312
24. Nagasaki H., Kosaka K., and Nakamura R. Disturbance of rhythm formation in patients with hemispheric lesion. Tohoku J Exp Med 135 (1981) 231-236
25. Hanakawa T., Katsumi Y., Fukuyama H., Honda M., Hayashi T., Kimura J., et al. Mechanisms underlying gait disturbance in Parkinson's disease: a single photon emission computed tomography study. Brain 122 Pt 7 (1999) 1271-1282
26. Picard N., and Strick P.L. Motor areas of the medial wall: a review of their location and functional activation. Cereb Cortex 6 3 (1996) 342-353
27. Kraus M.F., and Maki P.M. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiat Clin Neurosci 9 (1997) 222-230
28. Litvan I., Phipps M., Pharr V.L., Hallett M., Grafman J., and Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 57 3 (2001) 467-473